Trump, FDA to consider drug imports

As part of an effort to lower the price of prescription meds, the Trump administration is exploring ways to safely import certain drugs from foreign countries.

At the request of Secretary Secretary Alex Azar, the FDA is forming a working group to examine how the U.S. could import drugs from abroad “in the event of a dramatic price increase for a drug produced by one manufacturer and not protected by patents or exclusivities,” said the Department of Health and Human Services. Azar used Daraprim — a drug approved by the FDA in 1953 — as an example, citing its recent 5,000 percent price increase.

Because the drugs being considered for importation are off-patent and have no exclusivity remaining, the proposals contemplated by the working group would not dilute intellectual property rights or affect incentives for innovation, says HHS. Importation will be limited to cases where drugs can be imported with adequate assurances of safety and effectiveness.

Several drugmakers are joining the growing group of protestors who are distancing themselves from the Fox News Channel shows featuring Tucker Carlson and Jeanine Pirro after the hosts were accused of making bigoted statements.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.